Pfizer Inc. (PFE) Position Lifted by Northwest Wealth Management LLC

Northwest Wealth Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the fourth quarter, HoldingsChannel reports. The firm owned 12,621 shares of the biopharmaceutical company’s stock after acquiring an additional 336 shares during the period. Northwest Wealth Management LLC’s holdings in Pfizer were worth $551,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Vanguard Group Inc increased its holdings in Pfizer by 1.5% during the third quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after buying an additional 6,620,749 shares during the last quarter. Vanguard Group Inc. increased its holdings in Pfizer by 1.5% during the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after buying an additional 6,620,749 shares during the last quarter. Bessemer Group Inc. increased its holdings in Pfizer by 3,845.7% during the third quarter. Bessemer Group Inc. now owns 6,366,640 shares of the biopharmaceutical company’s stock worth $280,580,000 after buying an additional 6,205,282 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Pfizer by 3.7% during the third quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock worth $3,095,110,000 after buying an additional 2,497,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its holdings in Pfizer by 40.3% during the third quarter. Canada Pension Plan Investment Board now owns 7,552,926 shares of the biopharmaceutical company’s stock worth $332,857,000 after buying an additional 2,171,400 shares during the last quarter. 69.49% of the stock is currently owned by institutional investors.

PFE opened at $39.38 on Monday. The stock has a market capitalization of $234.42 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 2.37 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.57 and a quick ratio of 1.33. Pfizer Inc. has a twelve month low of $34.37 and a twelve month high of $46.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The company’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

In other news, insider Mikael Dolsten sold 149,553 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $43.55, for a total value of $6,513,033.15. Following the completion of the transaction, the insider now directly owns 390,097 shares in the company, valued at $16,988,724.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the transaction, the insider now owns 124,994 shares of the company’s stock, valued at $5,353,493.02. The disclosure for this sale can be found here. Insiders sold 332,526 shares of company stock valued at $14,346,539 over the last 90 days. 0.09% of the stock is owned by company insiders.

A number of research firms recently issued reports on PFE. JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price objective on shares of Pfizer in a report on Friday. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Bank of America raised their price objective on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Citigroup reiterated a “neutral” rating and issued a $41.00 target price on shares of Pfizer in a research note on Wednesday, February 20th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research note on Tuesday, February 19th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $45.61.

WARNING: This piece of content was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/pfizer-inc-pfe-position-lifted-by-northwest-wealth-management-llc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Analyst Ratings Trading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.